Hematology prior authorization at Centene
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Centene hematology PA at a glance
Centene reviews hematology PA submissions against its medical policy library, with rules drawn primarily from NCCN + ASH (American Society of Hematology). Centene-specific context: Largest Medicaid MCO in US. Markets under Ambetter (ACA), Wellcare (MA), and state-specific Medicaid brands. State-specific appeal processes vary; check state Medicaid handbook.
Documentation packet — what to send
- Diagnosis with ICD-10 (CLL, MM, NHL, etc.)
- Stage / risk stratification
- Molecular markers (BCR-ABL, TP53, IGHV, FISH)
- Prior lines of therapy with response
- Performance status
Common denial patterns to pre-empt
Patterns observed in hematology across payers, and where Centene's book of business overlaps:
- Off-label use (e.g., rituximab for non-Hodgkin's vs autoimmune)
- Indication-specific dosing
- Genetic testing (BCR-ABL, BRAF, TP53) not documented
- Step therapy in CLL / lymphoma
- Site of service for infusion
- Medicaid step therapy
Appeal angles when Centene denies
- NCCN Compendium citation for hematologic malignancy
- Molecular / cytogenetic test results supporting indication
- Performance status documentation
- Documented response/failure of prior lines
Peer-to-peer prep
- Bring the molecular pathology report
- Quote NCCN Compendium category (1, 2A, 2B)
- Reference the pivotal trial for the prescribed regimen
- Document prior-line response (CR, PR, SD, PD) explicitly
Drug-specific PA criteria at Centene
Deep dives on each drug's PA criteria at Centene:
Frequently asked questions
What documentation does Centene need for hematology prior authorizations?
Centene's PA packet for hematology typically includes: Diagnosis with ICD-10 (CLL, MM, NHL, etc.); Stage / risk stratification; Molecular markers (BCR-ABL, TP53, IGHV, FISH); Prior lines of therapy with response. NCCN + ASH (American Society of Hematology) citations strengthen the submission.
What's the turnaround at Centene?
Centene standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Medicare Advantage extension rule under 42 CFR Part 422 may add 14 days. Internal appeal window if denied: 60 days.
Which hematology drugs does Centene most often PA-restrict?
Top targets in hematology: rituximab, imatinib, ibrutinib, lenalidomide, apixaban. Each follows the per-drug step therapy + documentation requirements published in Centene's medical policy library.
How do I prep a peer-to-peer with Centene in hematology?
Bring the molecular pathology report Quote NCCN Compendium category (1, 2A, 2B) Have the policy URL and the patient's chart open before the call.
Generate a Hematology PA packet
Open ApprovalHelp — generate a hematology PA packet tailored to Centene's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com